<DOC>
	<DOCNO>NCT02137226</DOCNO>
	<brief_summary>Primary Objective : The primary objective trial establish equivalence efficacy BI 695501 US-licensed Humira® patient active RA base statistical comparison proportion patient meet American College Rheumatology 20 % ( ACR20 ) response rate Week 12 ACR20 response rate Week 24 BI 695501 US-licensed Humira® . Secondary Objectives : The secondary objective trial compare efficacy , safety immunogenicity BI 695501 US-lisensed Humira® patient active RA include undergoing transition US-licensed Humira® BI 695501 24 week .</brief_summary>
	<brief_title>BI 695501 Compared Adalimumab Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion criterion : All patient must sign date Informed Consent Form consistent International Conference Harmonisation Good Clinical Practice ( ICH GCP ) guideline local legislation prior participation trial ( i.e . prior trial procedure , include medication washout restriction ) willing follow protocol . Male female participant , 18 80 year age , diagnosis moderately severely active RA least 6 month define least six swollen joint ( 66 joint count ) least six tender joint ( 68 joint count ) Screening Baseline ( Day 1 ) , either ESR &gt; 28 mm/hour OR Creactive protein ( CRP ) level &gt; 1.0 mg/dL ( normal : &lt; 0.4 mg/dL ) Screening . Patients must currently receive methotrexate ( MTX ) therapy . Current treatment RA outpatient basis : 1 . Must receive tolerate oral parenteral MTX therapy dose 15 25 mg per week ( dose may low 10 mg per week patient unable tolerate high dose ) least 12 week immediately prior Day 1 . The dose administration route remain stable least 4 week prior Day 1 Week 24 . After Week 24 administration route change investigator 's discretion . Patients receive low dose MTX ( 10 14 mg/week ) result document history intolerance high dos MTX . 2 . Patients must willing receive oral folic acid ( least 5 mg/week per local practice ) folinic acid ( least 1 mg/week per local practice ) equivalent entire trial ( mandatory comedication MTX treatment ) . 3 . Disease modify antirheumatic drug ( DMARD ) use restrict accord guideline list trial protocol . 4 . If receiving current treatment oral corticosteroid ( intraarticular parenteral ) , dose must exceed 10 mg/day prednisolone equivalent . During 4 week prior Baseline ( Day 1 ) dose must remain stable . 5 . Any concomitant nonsteroidal antiinflammatory drug ( NSAIDs ) must stable least 2 week prior Day 1 . 6 . Patients may take oral hydroxychloroquine provide dose great 400 mg/day chloroquine provide dose great 250 mg/day . These dos must stable minimum 12 week prior Day 1 . The hydroxychloroquine chloroquine treatment need continue stable dose formulation end trial . For participant reproductive potential ( male female ) , reliable mean contraception use throughout trial participation ( acceptable method birth control include example birth control pill , intrauterine device [ IUDs ] , surgical sterilization , vasectomized partner double barrier method.. All patient ( male females childbearing potential ) must also agree use acceptable method contraception 6 month follow completion discontinuation trial medication . Exclusion criterion : ACR functional Class IV wheelchair/bed bound . Primary secondary immunodeficiency , include know history HIV infection , positive test Screening . History TB , latent TB , positive purify protein derivative test interferon gammareleasing assay . Known clinically significant coronary artery disease significant cardiac arrhythmia severe congestive heart failure , interstitial lung disease . Previous treatment &gt; =2 biologic agent . Previous treatment adalimumab adalimumab biosimilar . Current treatment previous treatment leflunomide within 8 week . History severe allergic reaction anaphylactic reaction biological agent history hypersensitivity adalimumab component trial drug . History cancer include solid tumor , hematologic malignancy , carcinoma situ . Has evidence positive serology HBV HCV . Receipt live/attenuated vaccine within 12 week prior Screening Visit . Patients expect receive live virus bacterial vaccination trial , 3 month last dose trial drug . Any treatment , opinion investigator , may place patient unacceptable risk trial . Patients significant disease RA and/or significant uncontrolled disease ( , limit , nervous system , renal , hepatic , endocrine , gastrointestinal disorder ) . A significant disease define disease , opinion investigator , may ( ) put patient risk participation trial , ( ii ) influence result trial , ( iii ) cause concern regard patient 's ability participate trial . Premenopausal , sexually active woman pregnant nursing , childbearing potential practicing acceptable method birth control , plan continue practice acceptable method birth control throughout trial . History , current , inflammatory joint disease RA systemic autoimmune disorder . Diagnosis juvenile idiopathic arthritis , and/or RA age 16 . Any planned surgical procedure within 12 week prior Screening Visit duration trial . Known active infection kind ( exclude fungal infection nail bed ) , major episode infection require hospitalization treatment intravenous anti infectives within 4 week Screening Visit completion oral antiinfectives within 2 week Screening Visit . History deep space/tissue infection within 52 week Screening Visit . History serious infection opportunistic infection last 2 year . Any neurological , vascular systemic disorder might affect efficacy assessment . Currently active alcohol drug abuse history alcohol drug abuse within 2 year Screening Visit . Treatment intravenous Gamma Globulin Prosorba® Column within 6 month Screening Visit . Treatment intravenous , intramuscular , intraarticular parenteral corticosteroid within 6 week prior Day 1 throughout trial . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 1.5 time upper limit normal . Hemoglobin &lt; 8.0 g/dL . Platelets &lt; 100,000/µL . Leukocyte count &lt; 4000/µL . Creatinine clearance &lt; 60 mL/min . Patients currently participate another clinical trial participate another clinical trial another investigational drug within minimum 12 week five halflives ( whichever longer ) drug prior Day 1 . Patients history clinically significant adverse reaction murine chimeric protein .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>